ARCH Venture Partners and affiliated entities filed Amendment No. 8 to their Schedule 13D with the SEC on November 6, 2026, disclosing share sales in Vir Biotechnology, Inc. common stock between November 3 and November 5, 2026.
Key Highlights
- Shares sold: ARCH Venture Fund IX, L.P. sold 347,819 shares and ARCH Venture Fund IX Overage, L.P. sold 448,356 shares of Vir Biotechnology common stock from November 3 to November 5, 2026.
- Remaining aggregate holdings: Each of the fund-level reporting persons reports aggregate beneficial ownership of 11,897,988 shares, representing 6.9% of the class.
- Individual holdings - Robert Nelsen: Reported aggregate beneficial ownership of 12,508,029 shares, representing 7.3% of the class, including 576,148 shares with sole voting and dispositive power.
- Individual holdings - Keith Crandell: Reported aggregate beneficial ownership of 12,170,952 shares, representing 7.1% of the class, including 272,964 shares with sole voting and dispositive power.
- Individual holdings - Clinton Bybee: Reported aggregate beneficial ownership of 11,989,718 shares, representing 7.0% of the class, including 30,570 shares with sole voting and dispositive power.
- Triggering event date: The date of the event requiring this filing is listed as November 4, 2026.
ARCH Venture Discloses November 2026 Share Dispositions in Vir Biotechnology
According to the filing, this Amendment No. 8 amends the original Schedule 13D filed on November 8, 2019, relating to the common stock, $0.0001 par value per share, of Vir Biotechnology, Inc., whose principal executive offices are located at 1800 Owens Street, Suite 900, San Francisco, California 94158. The reporting group is affiliated with ARCH Venture Management, LLC, based in Chicago, Illinois.
The filing discloses that from November 3, 2026 to November 5, 2026, ARCH Venture Fund IX, L.P. sold 347,819 shares of common stock for cash, and ARCH Venture Fund IX Overage, L.P. sold 448,356 shares of common stock for cash. The filing does not specify the per-share sale prices for these transactions. Each of the fund-level entities, including ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., and ARCH Venture Partners IX, LLC, reports shared voting and shared dispositive power over 11,897,988 shares, representing 6.9% of the class, with no sole voting or dispositive power.
The filing states that the common stock was acquired for investment purposes. According to the filing, "Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF IX and AVF IX Overage and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer." The filing further states that, except as described, none of the reporting persons has any present plans relating to an extraordinary corporate transaction, change in board composition, or material change in capitalization.
What Was Disclosed
ARCH Venture and affiliated reporting persons filed Amendment No. 8 to their Schedule 13D for Vir Biotechnology, disclosing the sale of a combined 796,175 shares between November 3 and November 5, 2026, with aggregate beneficial ownership remaining at approximately 6.9% to 7.3% depending on the reporting person.



Please wait processing your request...